Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 25, 2019

Primary Completion Date

April 4, 2022

Study Completion Date

April 4, 2022

Conditions
Cognitive DeclineChemo-brain
Interventions
DRUG

Memantine

"memantine dose~* Week 1: 5 mg dose once daily~* Week 2: 5 mg dose twice daily~* Week 3: 5 mg each morning/10 mg each evening~* Week 4 through the end of Chemotherapy: 10 mg dose twice daily~* Total duration: 12 - 26 weeks (depending on chemotherapy regimen)"

Trial Locations (1)

27514

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT04033419 - Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer | Biotech Hunter | Biotech Hunter